Geoffrey Shouse, DO, PhD

home / authors / geoffrey-shouse-do-phd

Articles

Geoffrey Shouse, DO, PhD

Dr Shouse on the Importance of NGS Testing in Follicular Lymphoma

Geoffrey Shouse, DO, PhD
August 22nd 2024

Geoffrey Shouse, DO, PhD, discusses the importance of performing next-generation sequencing in patients with follicular lymphoma.

Read More

Geoffrey Shouse, DO, PhD

Dr Shouse on AEs Associated With Targeted Therapies in FL

Geoffrey Shouse, DO, PhD
August 20th 2024

Geoffrey Shouse, DO, PhD, discusses adverse effects associated with targeted therapies used to treat patients with follicular lymphoma.

Read More

Geoffrey Shouse, DO, PhD

Dr Shouse on Currently Available Targeted Therapies for FL

Geoffrey Shouse, DO, PhD
August 13th 2024

Geoffrey Shouse, DO, PhD, discusses currently available targeted therapies for the management of follicular lymphoma.

Read More

Latest Updated Articles

Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
OncLive
Published: September 12th 2024 | Updated: September 17th 2024
State of the Science Summit - Breast Cancer: Chaired by Jairam Krishnamurthy, MD, FACP
Peter Schmid, MD, PhD, Barts College
Published: September 15th 2024 | Updated: September 17th 2024
Neoadjuvant Pembrolizumab/Chemo, Adjuvant Pembrolizumab Boosts OS in Early TNBC